Replimune REPL
NASDAQ REPL
$11.75 +0.03 (+0.26%)
As of: Oct 22, 2026 · 11:02 AM EDT

Replimune (REPL) Price to Sales (2018)

Updated

Analysis

Replimune (REPL) Price to Sales (2018) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,171.06 Bn 1,139.65 Bn 19.71 Bn
2 Johnson & Johnson 634.89 Bn 553.42 Bn 17.26 Bn
3 AbbVie 503.32 Bn 476.44 Bn 12.70 Bn
4 Merck 377.44 Bn 331.82 Bn 12.21 Bn
5 Novartis Ag 303.91 Bn 267.90 Bn 11.24 Bn
6 Astrazeneca 267.03 Bn 240.72 Bn 12.86 Bn
7 Amgen 241.88 Bn 197.28 Bn 7.24 Bn
8 Gilead Sciences 194.01 Bn 168.20 Bn 6.22 Bn
9 Pfizer 172.57 Bn 119.21 Bn 10.94 Bn
10 Replimune 1.14 Bn 81.16 Mn -
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2018 175.29
Sep 30, 2018 424.06
API Access

Replimune Price to Sales API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=price-to-sales&ticker=REPL&period=max&api_key=YOUR_API_KEY